Health
Immunotherapy extends survival in patients with advanced bladder cancer – News-Medical.Net
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Cent…
Reviewed by Emily Henderson, B.Sc.Sep 18 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
The resul…
-
Noosa News23 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane
-
Noosa News13 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General8 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
General9 hours agoChoosing an online exercise program can be confusing. Here’s what to look out for